Literature DB >> 27251358

Angiotensin II type 1 receptor antibodies in childhood kidney transplantation.

Anna Bjerre1, Trine Tangeraas1, Harald Heidecke2, Duska Dragun3, Ralf Dechend4, Anne Cathrine Staff5.   

Abstract

Angiotensin II type 1 receptor antibodies (AT1 RAb) have emerged as non-HLA Ab present in patients with acute AMR and risk of graft loss. Furthermore, AT1 RAb have been shown to increase angiotensin II sensitivity which may play a role in the development of CVD and hypertension. Data on AT1 RAb in stable transplant recipients are lacking. The aim of this study was to analyze the levels of AT1 RAb in a cohort of stable patients after kidney transplantation (tx) in childhood. A cross-sectional study of 30 children (median age 14, range 3-19 yr, median time since tx five yr) and 28 adults who were transplanted in childhood (median age 26, range 20-40 yr, median time since tx 18 yr) transplanted between 1993-2006 and 1983-2002, respectively, was performed. Healthy controls were 51 healthy children (5-8 yr) and 199 healthy donors (median age 56.5 yr, range 42-83 yr). Plasma AT1 RAb were analyzed by immunoassay. Median total AT1 RAb IgG concentration was significantly higher in the pediatric-tx group as compared to the adult-tx group (40.0 and 10.95 U/mL, p < 0.0001). For both groups, the tx group showed higher levels: the pediatric-tx group vs. control group (40.0 vs. 13.3 U/mL, p = 0.0006) and the adult-tx group vs. adult control group (10.95 vs. 6.5 U/mL, p < 0.0001). Age was the strongest indicator of high levels of AT1 RAb IgG (p = 0.0003). AT1 RAb total IgG levels are significantly higher in a stable pediatric-tx cohort as compared to adult-tx patients and healthy controls of comparable age groups. The relevance of our findings in relation to age, time since tx, previous or future rejection, and CVD risk merits future studies.
© 2016 The Authors. Pediatric Transplantation Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  angiotensin II type 1 receptor antibodies; cardiovascular disease; children; hypertension; kidney transplantation; rejection

Mesh:

Substances:

Year:  2016        PMID: 27251358     DOI: 10.1111/petr.12728

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  6 in total

1.  Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation.

Authors:  Meghan H Pearl; Qiuheng Zhang; Miguel Fernando Palma Diaz; Jonathan Grotts; Maura Rossetti; David Elashoff; David W Gjertson; Patricia Weng; Elaine F Reed; Eileen Tsai Chambers
Journal:  Kidney Int       Date:  2017-09-18       Impact factor: 10.612

Review 2.  Antibodies against Angiotensin II Type 1 and Endothelin A Receptors: Relevance and pathogenicity.

Authors:  Mary Carmelle Philogene; Tory Johnson; Arthur Jason Vaught; Sammy Zakaria; Neal Fedarko
Journal:  Hum Immunol       Date:  2019-04-19       Impact factor: 2.850

3.  Endothelin Type A Receptor Antibodies Are Associated With Angiotensin II Type 1 Receptor Antibodies, Vascular Inflammation, and Decline in Renal Function in Pediatric Kidney Transplantation.

Authors:  Meghan H Pearl; Lucia Chen; Rim ElChaki; David Elashoff; David W Gjertson; Maura Rossetti; Patricia L Weng; Qiuheng Zhang; Elaine F Reed; Eileen Tsai Chambers
Journal:  Kidney Int Rep       Date:  2020-09-06

Review 4.  Emerging monitoring technologies in kidney transplantation.

Authors:  Abdulla Ehlayel; K'joy J A Simms; Isa F Ashoor
Journal:  Pediatr Nephrol       Date:  2021-02-01       Impact factor: 3.714

Review 5.  Non-HLA Antibodies in Kidney Transplantation: Immunity and Genetic Insights.

Authors:  Bogdan Marian Sorohan; Cătălin Baston; Dorina Tacu; Cristina Bucșa; Corina Țincu; Paula Vizireanu; Ioanel Sinescu; Ileana Constantinescu
Journal:  Biomedicines       Date:  2022-06-25

Review 6.  Antibodies against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies.

Authors:  Giovanni Civieri; Laura Iop; Francesco Tona
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.